Canon Inc. · TSE:7751
Canon — Canon 2024 Corporate Strategy Conference
12 slides from Canon's conference presentation, Mar 8, 2024
Slide 1: Medical Group
Canon Inc. 2024 Corporate Strategy Conference Medical Group March 8, 2024 Toshio Takiguchi Senior Managing Executive Officer Head of Medical Group This presentation contains forward-looking statements with respect to future results, performance and achievements that are subject to risk and uncertain
Slide 2: P&L Net sales Profit ratio
P&L Net sales Profit ratio (Billions of yen) 700 12% Net sales Profit ratio 10% or more 600 10% 500 8% 7.9% 400 600 or more 6% 6.1% 300 6.0% 5.7% 582.0 553.8 4% 200 513.3 480.4 2% 100 0 0% 2021 2022 2023 2024 2025 2
Slide 3: Growth Strategy
Growth Strategy Basic 2020 to 2022 – Focus on strengthening internal structure to raise 2023 Stage 2 2025 Policy organizational strength and grow top line from 2023 2020 Stage 1 2022 短期 2020～2022年 Realize growth through strengthened structure and Prepare growth engines prepared growth engines Aim fo
Slide 4: Results up to 2023 & Challenges (Sales Growth)
Results up to 2023 & Challenges (Sales Growth) 億円 System Business Net Sales Results 500 billion yen or more Since 2019, over four year Operating profit ratio period, increased sales more ４00 billion yen or more than 100 billion yen 300 billion yen or more Challenges Net Sales 200 billion yen or more
Slide 5: Results up to 2023 & Challenges (Enhance Product Strength)
Results up to 2023 & Challenges (Enhance Product Strength) Raise clinical value through AI tech. Expand sales of MRI systems manufactured solely Canon • Low-dose radiation high-resolution • Enable high-quality image technology (AiCE) resolution in a short period of • Super resolution deep-learning t
Slide 6: Results up to 2023 & Challenges (Enhance Sales Capability)
Results up to 2023 & Challenges (Enhance Sales Capability) Enhance Sales Capability in U.S. • Accelerate upstream marketing activities in collaboration with Canon Healthcare USA, INC. • Promote alliance & co-research with Cleveland Clinic • Expand subscription sales process with NXC focus Develop sa
Slide 7: Results up to 2023 & Challenges (Enhance Business Constitution and Structure)
Results up to 2023 & Challenges (Enhance Business Constitution and Structure) Cost reduction measures • Contribute to profit through product quality improvement, promoting concurrent engineering in a concerted Canon Group effort • Begin sales of flagship CT system that is equipped with a new Operati
Slide 8: Results up to 2023 & Challenges (Optimize Portfolio)
Results up to 2023 & Challenges (Optimize Portfolio) Canon ✕ Minaris Synergy Equipment Reagents Build & realize strategy for further growth In 203X, achieve 100 billion yen in IVD business sales Synergy Phase 3 Synergy Phase 2 Develop immunoreagents that can be used in biochemistry through the Syner
Slide 9: 2025 Targets & Structural Reform
2025 Targets & Structural Reform Improve Profit 2025 Target 4 Key Actions Op. Profit Ratio To grow medical business into Achieve sales target 10% or higher (Sustaining innovation & true pillar portfolio optimization) Inauguration of Medical Business Innovation Committee Net sales 600 billion yen or
Slide 10: Strategies & Measures Over Next Two Years
Strategies & Measures Over Next Two Years Improve Profit ✓ Provide service solutions that maximize customer 4 Key Actions asset value at a minimum cost • Steady release new products and new technologies Ensure Improve Optimize Achieve sales target • IVD business expansion (Maximize synergies with op
Slide 11: Direction of Medical Group – Contribute to Precision Medicine
Direction of Medical Group – Contribute to Precision Medicine Current business areas Business expansion area Test & Diagnosis Solutions that support personalized therapy Specimen testing Pathological Realize Clinical In-Vitro & Bio diagnosis Liquid biopsy Genetic testing Decision Support Regenerativ
Slide 12: Canon
Canon